Heal Prevent Preserve Sleep Menopause Fertility Book a Visit
The Menopause Program
Vol. 02 · 2026
San Francisco · Los Angeles · Washington, DC
An essay in two systems

Half of humanity
will live a third of life
past their last period.

The Question
Why is the most predictable hormonal transition in human biology still treated as a surprise?
The Method
Modern hormone therapy. Microbiome diagnostics. One physician who reads both.
The Result
Symptoms quieted. Bones, brain, and heart protected. More time for life.
I.The Premise

Menopause is not a deficiency. It is a transition — the longest, most predictable hormonal shift in human biology, and the one modern medicine has handled the worst. For two decades after a single misread 2002 study, women were told their symptoms were a small price for safety. The science has long since moved on. The conversation in most exam rooms has not.

The result: a generation of women navigating hot flashes, sleep loss, brain fog, bone loss, vaginal pain, and rising cardiovascular risk without a serious medical partner. The most well-characterized endocrine event in adult medicine became the one patients had to research themselves.

And while estrogen was being debated, a second system was quietly shifting alongside it — the gut. The estrobolome — the community of microbes that decide how much of your estrogen gets recycled and how much is lost — collapses through the menopause transition in ways most clinicians have never been taught to look for, much less treat. We were trained to look at both. So we do.

II.   The Math

If you live to ninety, you will spend roughly forty years past your last period — longer than your reproductive life, longer than your childhood, longer than any other distinct chapter of adulthood.

A 90-year female life · proportional
50 yrs · before
8 yrs · transition
32 yrs · after
BIRTH 30 ~45 perimeno ~51 meno ~58 90
~7+ yrs
Average duration of vasomotor symptoms — hot flashes and night sweats — across the menopause transition. For many women, well over a decade.
~5%
Share of U.S. women in the menopausal age range currently prescribed any form of hormone therapy — down from roughly 40% before the 2002 WHI scare.
1 in 2
Postmenopausal women who will experience an osteoporotic fracture — an outcome modern hormone therapy substantially reduces when initiated in the right window.
"

Estrogen does not just leave.
It cycles back — through your gut — until it doesn't.
We treat both halves.

— The case for measuring the estrobolome
III.   The Problem

Most menopause goes medically unaddressed — and most of what's offered hasn't caught up to the science.

The post-WHI generation of physicians were trained to fear hormone therapy. The patients who actually need it are now in midlife, and the medical system has spent twenty years catching up. The result is a credibility gap big enough to fall through.

80%
of menopausal women report symptoms that affect daily life. Most are never asked about them in a primary care visit, and most never raise them.
20%
of OB/GYN residents in the U.S. report receiving any meaningful menopause training in residency. The cohort tasked with caring for this transition was never taught the medicine.
10yrs
— the "window of opportunity" after menopause within which hormone therapy has its most favorable risk-benefit profile. Missed routinely, because no one was watching for it.
$26B
in annual U.S. productivity loss attributed to untreated menopausal symptoms. A workforce running on broken sleep and unaddressed cognition — and a problem with a treatment.

From your first visit to your protocol, in under three weeks.

A modern menopause workup looks at hormones, bones, lipids, glucose, thyroid, sleep, and the microbiome that recycles your estrogen — read together by a physician who actually has time to read them.

Step 01 / Measure

The full workup.

A single comprehensive draw: estradiol, FSH, LH, progesterone, testosterone, SHBG, thyroid panel, lipid panel, HbA1c, vitamin D, and high-sensitivity CRP. Stool microbiome — diversity index, beneficial taxa, β-glucuronidase activity. Vaginal microbiome panel if symptoms warrant. DEXA scan for baseline bone density.

In-clinic visit  ·  at-home microbiome kit
Step 02 / Read

Your data, read together.

Your results come back through one chart, not seven. Our clinical decision-support layer flags patterns a single result wouldn't show — low estradiol paired with low microbial diversity, vaginal dysbiosis paired with rising urinary symptoms, thyroid drift masking what looks like menopausal fatigue. Your physician makes the call.

Pattern-aware  ·  physician-led always
Step 03 / Treat

A plan, not a prescription pad.

Hormone therapy when indicated — FDA-approved, route-optimized, dose-titrated to your bloodwork. Targeted probiotics by strain name, not by aisle. Vaginal estrogen if symptoms call for it. Bone, brain, heart, and sleep tracked longitudinally on the same chart. Your AI walks home with you — narrating the plan in plain English and translating new results as they arrive. Follow-up already booked.

Evidence-based  ·  longitudinal
IV.   The Program

Three systems, one visit.

Menopause is not one problem with one drug. It is a coordinated change across the endocrine system, the gut, and the urogenital tract — and the only way to treat it well is to treat all three.

Tier I
Hormone restoration.
The Endocrine Side
FDA-approved hormone therapy, modern formulations, individualized routes and doses. We do not prescribe compounded "bioidentical" pellets or creams; the evidence does not support them and the FDA does not regulate them. We use medications with peer-reviewed safety data.
Transdermal estradiolFirst Line
Patch · Gel · Spray
Delivered through the skin, bypassing the liver. Lower clot risk than oral estrogen, and the formulation most modern guidelines favor for women initiating therapy. Dose titrated to symptoms and bloodwork — not to a single starter strength.
Oral micronized progesteroneFirst Line
Nightly · for women with a uterus
Bio-identical to the progesterone your body once made, with a sedating side effect most women appreciate at bedtime. Preferred over the synthetic progestins implicated in the original WHI signal.
Vaginal estrogenHigh-Impact
Cream · Tablet · Ring
Local, low-dose, and dramatically under-prescribed. Treats vaginal dryness, painful intercourse, and the recurrent UTIs that follow estrogen loss. Considered safe even for many breast cancer survivors under appropriate oncology guidance.
Testosterone (selected cases)
Topical · Off-label
For women with persistent low libido or sexual dysfunction after estrogen optimization. Prescribed conservatively, at female physiologic doses, with monitoring. Not a wellness drug — a targeted tool.
Non-hormonal pharmacotherapy
For women who can't or won't take HRT
SSRIs/SNRIs for vasomotor symptoms, gabapentin for night sweats, and the newer NK3-receptor antagonists (fezolinetant) for women in whom hormones are contraindicated. The full toolkit, not just one drawer.
Ongoing titration
Quarterly first year · then biannual
Hormone therapy is not "start it and forget it." We re-check labs, symptom scores, blood pressure, and lipids on a real schedule — and adjust accordingly. The dose that worked at year one is rarely the dose for year five.
Tier II
The estrobolome.
The Microbial Side
A specific community of gut microbes — collectively called the estrobolome — produces β-glucuronidase, the enzyme that frees conjugated estrogens in the gut so they can be reabsorbed. When this community shifts, so does your circulating estrogen. We test for it. Most clinics don't.
Stool microbiome panelBaseline
16S / shotgun sequencing · at-home kit
Diversity index, ratio of key phyla, presence of beneficial taxa (Akkermansia muciniphila, Faecalibacterium prausnitzii), inflammatory markers, and where indicated, β-glucuronidase activity. Read alongside your hormone panel, not in isolation.
Vaginal microbiome panelSymptom-Triggered
Self-collected swab
Quantifies Lactobacillus dominance and dysbiotic species (Gardnerella, Atopobium). Estrogen loss collapses vaginal glycogen, which collapses Lactobacillus, which raises pH and drives recurrent UTIs, BV, and atrophy. Naming the bug tells us what to do.
Inflammatory & permeability markers
Stool · selective
Calprotectin, secretory IgA, and selected permeability markers when symptoms suggest gut inflammation or post-menopausal IBS-like patterns. Sorting "menopause" from "this looks like menopause but isn't."
Dietary fiber and polyphenol protocol
Prescribed · monitored
The estrobolome feeds on fermentable fiber and specific polyphenols. We give you a written, practical food protocol — not a 40-page wellness PDF — and we track diversity on follow-up testing to see whether it's working.
Tier III
Probiotics, by name.
Targeted Strains
"Probiotic" is not a product — it's a category, and most products on the shelf have no evidence for the use they're sold for. We prescribe specific strains with peer-reviewed evidence for specific indications. We do not sell them. You buy them at the pharmacy.
L. rhamnosus GR-1 + L. reuteri RC-14Urogenital
Oral · daily
The most-studied probiotic pair for urogenital and vaginal health in women. Oral dosing colonizes the vaginal tract. Used for recurrent UTI prevention and vaginal dysbiosis, often alongside vaginal estrogen.
L. crispatus CTV-05Vaginal
Vaginal · NEJM-published
A live-biotherapeutic strain with randomized-trial evidence for preventing recurrent bacterial vaginosis. Recolonizes the Lactobacillus niche that menopause depletes. Prescribed selectively, based on swab results.
Akkermansia muciniphilaMetabolic
Pasteurized · oral
Reduced abundance is linked to insulin resistance and weight gain — both of which worsen across the menopause transition. The pasteurized form has favorable human safety data and a randomized metabolic-outcomes trial behind it.
L. reuteri ATCC PTA 6475Bone
Adjunct to bone protocol
A specific L. reuteri strain with randomized-trial evidence for slowing bone loss in older women. An adjunct — not a replacement — for HRT and weight-bearing exercise in our bone-health protocol.
Bifidobacterium animalis lactis BB-12
General gut · well-tolerated
One of the best-studied general-purpose probiotic strains. Used when stool testing shows reduced Bifidobacterium abundance — a common finding through the menopause transition.
L. plantarum 299v
IBS-like symptoms · oral
Specific strain evidence for bloating, abdominal discomfort, and altered bowel patterns — a constellation that frequently emerges in perimenopause and is often misattributed to "just stress." We test, then prescribe by strain.
V.   The Two Curves

Menopause is not one decline. It's two — and they pull on each other.

Estrogen drops. The microbiome shifts. Each amplifies the other. Most clinics treat one curve and pretend the other isn't there. The estrobolome is where the two systems meet.

HORMONES & MICROBIOME · Across the menopause transition Age 35 → 65
HIGH LOW THE TRANSITION Estradiol Gut microbial diversity Vaginal Lactobacillus Bone density AGE 35 45 · PERI ~51 · MENO 58 · POST 65
THE ESTROBOLOME · Enterohepatic recirculation of estrogen Why the gut is an endocrine organ
Ovaries PRODUCE estrogen Liver CONJUGATES via bile Gut microbiome β-GLUCURONIDASE the estrobolome deconjugated estrogen, reabsorbed THE LOOP A specific community of gut microbes — the estrobolome — decides how much of your estrogen comes back — and how much is lost.

Endocrine

HORMONE PANEL

Estradiol, FSH, progesterone, testosterone, SHBG, thyroid. The endocrine baseline that every menopause plan should start with — and most don't.

Microbial

STOOL · VAGINAL

Diversity, key taxa, β-glucuronidase, Lactobacillus dominance. The half of menopause physiology no one was screening for ten years ago.

Structural

BONE · CARDIO · METABOLIC

DEXA, lipid panel, HbA1c, blood pressure. The long-horizon outcomes that hormone therapy in the right window can substantially shift.

VI.   What Changed

Twenty-four years after WHI, the consensus has moved. The exam-room conversation hasn't.

What 2002 Taught a Generation

The fear we inherited.

  • HRT raises breast cancer risk uniformly, for every woman, at every age.
  • All hormones are the same; route and formulation don't matter.
  • "Use the lowest dose for the shortest time" — even when symptoms persist.
  • Vaginal estrogen carries the same systemic risks as oral.
  • Compounded "bioidenticals" are safer because they're "natural."
What the Evidence Now Says

The medicine we practice.

  • For women under 60 or within 10 years of menopause, hormone therapy has a favorable risk-benefit profile for most.
  • Transdermal estradiol does not carry the same clot risk as oral; route matters.
  • Micronized progesterone has a more favorable breast safety profile than the synthetic progestins used in WHI.
  • Low-dose vaginal estrogen is local, minimally absorbed, and safe for most women — including many breast cancer survivors under oncology guidance.
  • Compounded pellets and creams are not FDA-regulated and are not endorsed by any major society.

Menopause doesn't sit in a silo. Neither does our care.

Hot flashes are the most visible part of menopause and the least medically important. The transition silently reshapes weight regulation, cardiovascular risk, bone strength, brain health, sleep, and sexual function — every one of which we manage on the same chart, in the same practice, with the same physician.

Heal

Weight gain isn't willpower.

The menopause transition shifts fat distribution, drops resting metabolic rate, and worsens insulin sensitivity. GLP-1 therapy, hormone optimization, and gut microbiome work address the actual biology — not a "eat less, move more" lecture for a body that just rewrote its rules.
Prevent

The heart and bones watch the clock.

Cardiovascular disease becomes the leading cause of death in women after menopause. Bone loss accelerates in the first decade. Both respond meaningfully to hormone therapy initiated in the right window — and we are watching that window, even when you aren't.
Preserve

Fertility lives before this page.

For women in their thirties and early forties not yet in transition, the conversation is different: egg freezing, ovarian reserve testing, and an honest read of how much time remains. Our PRESERVE program runs the same biology, one chapter earlier.

Covered by insurance, because menopause is medicine.

Office visits, hormone panels, lipid panels, DEXA scans, FDA-approved hormone prescriptions, and follow-up visits are billed through insurance. Microbiome panels and advanced longitudinal monitoring are available as cash-pay add-ons. No membership required.

Aetna Blue Cross Blue Shield Cigna United Medicare CareFirst

Three cities, all already yours.

Now Accepting Patients

San Francisco

305 Spear St
Embarcadero
Book a Menopause Consult →
Now Accepting Patients

Los Angeles

8500 Beverly Boulevard
Beverly Center
Book a Menopause Consult →
Now Accepting Patients

Washington, DC

825 10th St NW
City Center
Book a Menopause Consult →
Begin

A third of your life
deserves a plan.

Start with a conversation. We'll look at hormones, microbiome, bone, heart, and how you're sleeping — and build a written plan together. Most insurance accepted. First visits typically within the week.

Book a Menopause Consult
Available in Washington, DC  ·  San Francisco